Search results
Oppenheimer Reiterates Market Perform Rating for Editas Medicine (NASDAQ:EDIT)
ETF DAILY NEWS· 7 hours agoEditas Medicine (NASDAQ:EDIT – Get Free Report)‘s stock had its “market perform” rating restated by research analysts at Oppenheimer in a report issued on Tuesday, Benzinga ...
Perspective Therapeutics (NYSE:CATX) Rating Reiterated by Oppenheimer
ETF DAILY NEWS· 7 hours agoPerspective Therapeutics (NYSE:CATX – Get Free Report)‘s stock had its “outperform” rating restated...
Where to watch Oppenheimer: Stream the Best Picture winner from anywhere
INSIDER via Yahoo News· 2 days agoWhen you buy through our links, Business Insider may earn an affiliate commission. Learn more...
Is OOSAX a Strong Bond Fund Right Now?
Zacks via Yahoo Finance· 22 hours agoIf investors are looking at the Diversified Bonds fund category, make sure to pass over Oppenheimer Senior Floating Rate A (OOSAX). OOSAX bears a Zacks...
Emily Blunt lands next lead movie role
Digital Spy via Yahoo News· 4 days agoOppenheimer star Emily Blunt has landed her next lead movie role. The actor is set to star in Steven Spielberg's next film for Universal and Amblin,...
Oppenheimer Lowers Ovid Therapeutics (NASDAQ:OVID) to Market Perform
ETF DAILY NEWS· 2 days agoOvid Therapeutics (NASDAQ:OVID – Get Free Report) was downgraded by stock analysts at Oppenheimer from an “outperform” rating to a “market perform” rating in a report issued ...
Oppenheimer maintains bullish rating on Broadcom following management meeting By Investing.com
Investing.com· 6 days agoOppenheimer maintains bullish rating on Broadcom following management meeting
The Cool Connection Oppenheimer Actually Shares With The Big Bang Theory
Cinema Blend· 3 days agoWhat do Sheldon Cooper and J. Robert Oppenheimer have in common? This connection has everything to...
Normani Responds to Camila Cabello After She Congratulates Her on Release of 'Dopamine': 'This...
People via Yahoo News· 3 days agoAlberto Rodriguez/WWD via Getty Normani at the Vanity Fair x Saint Laurent x NBCUniversal '...
Oppenheimer Lowers Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $25.00
ETF DAILY NEWS· 1 day agoZentalis Pharmaceuticals (NASDAQ:ZNTL – Free Report) had its price objective trimmed by Oppenheimer from $50.00 to $25.00 in a report issued on Tuesday morning, Benzinga reports ...